Turning Point Therapeutics, Inc. announced the formation of a scientific advisory board to help guide the company’s early stage research and development of novel targeted therapies. The board includes prominent research leaders and pioneers in understanding oncogenic drivers and protein kinases that become dysregulated in cancer and other diseases. Members include: Kevan Shokat, Ph.D., professor, Department of Cellular and Molecular Pharmacology, UCSF; professor, Department of Chemistry, UC Berkeley; investigator, Howard Hughes Medical Institute. Dr. Shokat will chair the scientific advisory board; Benjamin Cravatt, Ph.D., chair of Chemical Biology and professor, Department of Chemistry, The Scripps Research Institute; Natalia Jura, Ph.D., assistant professor, Department of Cellular and Molecular Pharmacology, UCSF; and Michael Varney, Ph.D., advisor; former executive vice president, Genentech Research and Early Development.